Clinical trials: Myocardial Infarct
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Heart Diseases
Electrophysiological Effects of Late PCI After MI
The purpose of this study is to determine if opening blocked arteries with heart balloons and stents prevents heart rhythm problems in individuals 3 to 28 days after a heart attack.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Coronary Disease
- Trial name
- NCT00119847
- Testing
- PCI, Optimal Medical Therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Maryland, Baltimore
Myocardial Infarction
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Most of the previous data regarding the efficacy of the everolimus-eluting stent (EES) was derived from studies comparing EES with bare metal stent (BMS) or EES with paclitaxel-eluting (PES).
- Trial name
- EVERZOTA (NCT01347554)
- Testing
- Everolimus eluting stent, Zotarolimus eluting stent
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Yonsei University
Chest Pain, Coronary Artery Disease
Risk Markers in the Acute Coronary Syndromes
The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples…
- Conditions
- Chest Pain, Coronary Artery Disease, Unstable Angina Pectoris, Myocardial Infarction
- Trial name
- RACS (NCT00521976)
- Where
- Norway
- Volunteers
- 871 people
- Sponsor
- Helse Stavanger HF
Myocardial Infarction
Novel Biomarkers of Thrombotic Risk
Treatment of patients who have had a heart attack with drugs that prevent formation of blood clots has been shown to reduce the patient's risk of subsequent cardiovascular events such as heart attack, stroke, and death.
- Trial name
- NCT02505217
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Vermont
Cardiovascular Diseases, Myocardial Infarction
Subclinical Cardiovascular Disease in Psoriatic Disease
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
- Trial name
- NCT03228017
- Testing
- Aspirin and/or Atorvastatin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD III With the Shockwave Coronary IVL System
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic…
- Trial name
- NCT03595176
- Testing
- Lithotripsy
- Where
- 48 sites in United States, France and 2 more
- Volunteers
- 431 people
- Sponsor
- Shockwave Medical, Inc.
Mitral Valve Insufficiency, Mitral Valve Regurgitation
Pivotal Study of a Percutaneous Mitral Valve Repair System
EVEREST II Randomized Controlled Trial (RCT) is a prospective, multi-center, randomized study of the MitraClip® System in the treatment of mitral valve regurgitation, randomizing patients to MitraClip or mitral valve surgery.
- Conditions
- Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation
- Trial name
- EVERESTIIRCT (NCT00209274)
- Testing
- Percutaneous mitral valve repair using MitraClip implant, Mitral valve repair or replacement surgery
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- Abbott Medical Devices
ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease
Metformin to Reduce Heart Failure After Myocardial Infarction
The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic…
- Conditions
- ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
- Trial name
- GIPS-III (NCT01217307)
- Testing
- Metformin
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
ST-Elevation Myocardial Infarction
A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly…
- Trial name
- IC TITAN (NCT00719914)
- Testing
- eptifibatide, normal saline
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Brigham and Women's Hospital
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary…
- Trial name
- NCT00684021
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Coronary Artery Disease
The Medtronic RESOLUTE US Clinical Trial
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter…
- Trial name
- R-US (NCT00726453)
- Testing
- Resolute Zotarolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 1,516 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD IV With the Shockwave Coronary IVL System
The study design is a prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries…
- Trial name
- NCT04151628
- Testing
- Lithotripsy
- Where
- 8 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Shockwave Medical, Inc.
Cardiogenic Shock
Impella CP With VA ECMO for Cardiogenic Shock
Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock.
- Trial name
- REVERSE (NCT03431467)
- Testing
- Impella-CP LV Vent
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
Hypertension, Diabetes
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
ASCOT-10 is a follow-up study of surviving participants in the United Kingdom (UK)arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) which was conducted between 2000 and 2005.ASCOT's results showed substantial…
- Conditions
- Hypertension, Diabetes, Death From Cardiovascular Disease, Myocardial Infarction
- Trial name
- ASCOT-10 (NCT01499511)
- Where
- United Kingdom
- Volunteers
- 1,718 people
- Sponsor
- Imperial College London
Myocardial Infarction, Myocardial Infarction, Acute
BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction
The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors…
- Conditions
- Myocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old
- Trial name
- BIO-GUARD-MI (NCT02341534)
- Testing
- BioMonitor
- Where
- 59 sites in United States, Australia and 12 more
- Volunteers
- 802 people
- Sponsor
- Biotronik SE & Co. KG
Acute Myocardial Infarction, Coronary Artery Disease
Use of Intra-aortic Balloon Pump Before Surgery for Acute Myocardial Infarction
The optimal timing of surgery in patients with acute myocardial infarction (AMI) and the utilization of preoperative intra-aortic balloon pumps (IABP) in these patients are subjects of ongoing discussion and disagreement.
- Conditions
- Acute Myocardial Infarction, Coronary Artery Disease, Coronary Bypass Graft Stenosis of Autologous Vessel, Troponin
- Trial name
- NCT06468982
- Testing
- Intra-aortic Balloon Pump
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 156 people
- Sponsor
- Ataturk University
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC